Literature DB >> 11467800

The seroepidemiology of varicella in Italy.

G Gabutti1, C Penna, M Rossi, S Salmaso, M C Rota, A Bella, P Crovari.   

Abstract

We conducted a seroepidemiological study to evaluate the potential impact of mass varicella vaccination on the transmission of varicella-zoster virus (VZV) in Italy, where vaccination is not mandatory. We tested 3179 serum samples, collected from September 1996 to October 1997, for specific anti-VZV antibodies using a commercially available ELISA. The results confirmed that varicella typically involves children (82.1% seroprevalence among 10- to 14-year-olds) and that the mean age of acquiring the infection seems to be increasing. The results also revealed that southern Italy, compared to the rest of the country, has a greater circulation of VZV and an earlier age of acquisition. The potential impact of mass vaccination among 12- to 18-month-old children on the epidemiological trend of the infection must be carefully considered, in that failure to reach high levels of coverage could lead to an increase in the mean age of acquisition, which is already occurring in Italy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11467800      PMCID: PMC2869711          DOI: 10.1017/s0950268801005398

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  16 in total

1.  Deterministic SIR (Susceptible-Infected-Removed) models applied to varicella outbreaks.

Authors:  J Ospina Giraldo; D Hincapié Palacio
Journal:  Epidemiol Infect       Date:  2007-07-26       Impact factor: 2.451

Review 2.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

3.  Has VZV epidemiology changed in Italy? Results of a seroprevalence study.

Authors:  Antonella De Donno; Parvanè Kuhdari; Marcello Guido; Maria Cristina Rota; Antonino Bella; Giordana Brignole; Silvia Lupi; Adele Idolo; Armando Stefanati; Martina Del Manso; Giovanni Gabutti
Journal:  Hum Vaccin Immunother       Date:  2016-12-27       Impact factor: 3.452

4.  Varicella vaccination in Italy : an economic evaluation of different scenarios.

Authors:  Laurent Coudeville; Alain Brunot; Carlo Giaquinto; Carlo Lucioni; Benoit Dervaux
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  The epidemiology of varicella in school-aged Greek children before the implementation of universal vaccination.

Authors:  A Katsafadou; G Ferentinos; A Constantopoulos; V Papaevangelou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-16       Impact factor: 3.267

6.  Is there a change in cytomegalovirus seroepidemiology in Spain?

Authors:  F de Ory; R Ramírez; L García Comas; P León; M J Sagües; J C Sanz
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

7.  Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain).

Authors:  Lluís Salleras; Angela Domínguez; Pere Plans; Josep Costa; Neus Cardeñosa; Núria Torner; Antoni Plasència
Journal:  Med Microbiol Immunol       Date:  2007-11-15       Impact factor: 4.148

8.  Varicella vaccination in Europe: are we ready for a universal childhood programme?

Authors:  Nitu Sengupta; Robert Booy; H J Schmitt; Heikki Peltola; Pierre Van-Damme; R Fabian Schumacher; Magda Campins; Carlos Rodrigo; Terho Heikkinen; Jane Seward; Aisha Jumaan; Adam Finn; Per Olcén; Nancy Thiry; Catherine Weil-Olivier; Judith Breuer
Journal:  Eur J Pediatr       Date:  2007-03-03       Impact factor: 3.860

9.  The epidemiology of Varicella Zoster Virus infection in Italy.

Authors:  Giovanni Gabutti; Maria C Rota; Marcello Guido; Antonella De Donno; Antonino Bella; Marta L Ciofi degli Atti; Pietro Crovari
Journal:  BMC Public Health       Date:  2008-10-27       Impact factor: 3.295

10.  Seroepidemiology of varicella zoster virus infection in Vojvodina, Serbia.

Authors:  S Medić; V Petrović; V Milosević; Z Lozanov-Crvenković; S Brkić; N Andrews; F de Ory; C Anastassopoulou
Journal:  Epidemiol Infect       Date:  2018-06-18       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.